Papillary Thyroid Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Papillary Thyroid Cancer – Pipeline Review, H2 2016’, provides an overview of the Papillary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer

The report reviews pipeline therapeutics for Papillary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Papillary Thyroid Cancer therapeutics and enlists all their major and minor projects

The report assesses Papillary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Blueprint Medicines Corporation

Daiichi Sankyo Company, Limited

Ignyta, Inc.

Novartis AG

Pfizer Inc.

Synactix Pharmaceuticals, Inc.

Vaccinex, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Papillary Thyroid Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Papillary Thyroid Cancer - Overview 7

Papillary Thyroid Cancer - Therapeutics under Development by Companies 8

Papillary Thyroid Cancer - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Papillary Thyroid Cancer - Products under Development by Companies 12

Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 13

Blueprint Medicines Corporation 13

Daiichi Sankyo Company, Limited 14

Ignyta, Inc. 15

Novartis AG 16

Pfizer Inc. 17

Synactix Pharmaceuticals, Inc. 18

Vaccinex, Inc. 19

Papillary Thyroid Cancer - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

BLU-667 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

dabrafenib mesylate - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

entrectinib - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

everolimus - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

pasireotide - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

PLX-7486 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

PLX-8394 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

RXDX-105 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

sunitinib malate - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SYN-001 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

VX-15 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Papillary Thyroid Cancer - Dormant Projects 69

Papillary Thyroid Cancer - Discontinued Products 70

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

List of Tables

Number of Products under Development for Papillary Thyroid Cancer, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Papillary Thyroid Cancer – Pipeline by Blueprint Medicines Corporation, H2 2016 13

Papillary Thyroid Cancer – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 14

Papillary Thyroid Cancer – Pipeline by Ignyta, Inc., H2 2016 15

Papillary Thyroid Cancer – Pipeline by Novartis AG, H2 2016 16

Papillary Thyroid Cancer – Pipeline by Pfizer Inc., H2 2016 17

Papillary Thyroid Cancer – Pipeline by Synactix Pharmaceuticals, Inc., H2 2016 18

Papillary Thyroid Cancer – Pipeline by Vaccinex, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Papillary Thyroid Cancer – Dormant Projects, H2 2016 69

Papillary Thyroid Cancer – Discontinued Products, H2 2016 70

List of Figures

List of Figures

Number of Products under Development for Papillary Thyroid Cancer, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Top 10 Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports